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Material and Methods: Our cohort includes 15 pts (6 girls, 9 
boys) treated with RT for HL, in age 6-25 years (median 17) 
at the RT, from 2008 to 2013. The 15 pts are representative 
of different RT target volumes (e.g. bilateral neck, ipsilateral 
neck, mediastinum, mantel-field, lombo-aortic and spleen, 
inverted Y, inguinal field, or a combination of them). We 
calculated the excess absolute of risk (EAR) end the 
cumulative risk of “all solid” and “single organ” SMN: mouth 
and pharynx, parotids glands, thyroid, lung, stomach, small 
intestine, colon, liver, cervix, bladder, brain and spinal cord, 
skin, female breast, bone and soft tissue. Every HT plan has 
been compared with 3D-CRT plan, both for EAR, cumulative 
risk and target coverage. 
 
 
Results: The risk of SMN solids is high, for both techniques, 
for breast, lung, thyroid, skin and colon. Some HT treatments 
may lead to increased risk of SMN solid than 3D-CRT plans, 
depending on the patient's age at exposure, on the specific 
organ volume or target volume and on the dose-response of 
each site. All the HT plans have the best conformation to the 
target and the greatest homogeneity of the dose to it 
delivered (best conformation number and homogeneity 
index). 
 
 
In this table: EAR (/10000 pts-year) at agea 60 in HT and 3D-
CRT for all pts (1-15: pink=girl, cyan=boy); DT=target dose in 
cGy, agex= age at pt's radiation treatment, n= number of RT 
fractions.Green=max value for each line.Red= statistically 
significant EAR ratio with EAR HT>EAR 3D-CRT; blue= 
statistically significant EAR ratio with EAR 3D-CRT> EAR HT 
 
Conclusion: Even if HT increases the target coverage in all 
pts, it could increase the incidence of SMN compared with 
3D-CRT for long-term survivors, depending on single specific 
target, target volume and pts age. However, EAR estimates 
are affected by large uncertainties and more works should be 
performed to better understand the risk of SMN with modern 
RT techniques after a childhood cancer. 
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A central independent quality assurance (QA) process is 
acknowledged as an essential component of current 
radiotherapy clinical trials. QA processes are implemented 
both pre accrual and during accrual. The former ensures 
centres have the equipment, expertise and ability to comply 
with trial protocol requirements and that they are able to 
deliver treatment accurately and consistently. During accrual 
processes assure continued compliance and consistency of 
treatment delivery both within individual centres and across 
all recruiting centres throughout the trial. The key process 
areas in QA activity are: 
Target volume and organ at risk outlining 
Treatment planning and optimisation 
Treatment delivery and verification 
Dosimetry Audit 
This talk will focus on the following main themes expanding 
on the processes involved and providing evidence and 
examples from individual trial QA programmes. 
The implementation of clinical trial QA: Appropriate QA tasks 
to include questionnaires, process documents through review 
of example patient cases to dosimetry audit site visits, are 
assigned on an individual trial basis. The level of QA required 
will vary according to the complexity and novelty of the 
radiotherapy technique. 
Defining standards: It is well recognised that target volume 
and OAR delineation and treatment planning and optimisation 
may be variable and open to individual interpretation. 
Through multi professional trial workshops, provision of 
delineation guidelines and setting of dose-volume 
constraints, consensus benchmark standards can be defined. 
Assessment against a benchmark: Conformity metrics and 
pre-defined mandatory and optimal dose constraints can be 
used to review against consensus standards to highlight 
potential protocol variations. Historically this review has 
been retrospective; however increasing use of prospective 
evaluation with constructive feedback can allow correction of 
protocol variations before treatment is delivered.  
Verification of treatment delivery: Dosimetry audit in the 
form of a postal or site visit serves to provide an independent 
assessment of dose delivered and directly compares 
individual centres. Recently, resulting from advances in 
image guidance, adaptive radiotherapy has been introduced 
in the clinical trial setting, introducing new challenges in 
assessment of plan selection competency and compliance.  
As more advanced technology is introduced in the clinical 
trial setting, QA activities must continually evolve to provide 
a safe framework for implementation of technical 
radiotherapy. Increased participation in clinical trials 
demands a streamlined approach to QA to reduce workload, 
improve efficiency and facilitate opening centres for 
recruitment earlier. Participation in a comprehensive QA 
programme not only accredits the centre for recruitment but 
also benefits the general standard of RT delivered. 
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Radiotherapy (RT) planning and delivery for cancer 
management has substantially evolved over the last three 
decades with lately the introduction of intensity modulated 
RT, image-guided RT and stereotactic ablative RT to name a 
few techniques. The evaluation of these high precision 
delivery techniques in routine care and in clinical trials alike 
are error prone. They thus do require optimal RT quality 
(RTQA) assurance programs which aim at defining the range 
of acceptable variations and importantly developing 
mechanisms of action for correction and prevention of 
potential variations. RTQA outside a clinical trial is defined 
by all processes that ensure consistency of the dose 
prescription and the safe delivery of that prescription with 
regard to dose to the target and critical structures, 
minimization of the exposure of the RT personnel. In the 
framework of clinical trials assessing the efficacy of RT with 
or without a combined modality, RTQA is also necessary to 
avoid the corruption of the study-endpoint, as RT variations 
from study protocol decrease the therapeutic effectiveness 
